Published in final edited form as:

Adv Synth Catal. 2014 January 13; 356(1): 165–178. doi:10.1002/adsc.201300851.

A General and Practical Palladium-Catalyzed Direct α -Arylation of Amides with Aryl Halides

Bing Zheng^{a,b}, Tiezheng Jia^b, and Patrick J. Walsh^{b,*}

^aDepartment of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China.

^bRoy and Diana Vagelos Laboratories, Penn/Merck Laboratory for High-Throughput Experimentation, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.

Abstract

An efficient system for the direct catalytic intermolecular α -arylation of acetamide derivatives with aryl bromides and chlorides is presented. The palladium catalyst is supported by Kwong's indole-based phosphine ligand and provides monoarylated amides in up to 95% yield. Excellent chemoselectivities (>10:1) in the mono- and diarylation with aryl bromides were achieved by careful selection of bases, solvents, and stoichiometry. Under the coupling conditions, the weakly acidic α -protons of amides (pK_a up to 35) were reversibly deprotonated by LiO^tBu, NaO^tBu, or NaN(SiMe₃)₂.

Keywords

palladium; cross-coupling; C-C bond formation; amides; aryl halides; chemoselectivity

Introduction

Amides are synthetically versatile intermediates for the synthesis of biologically active molecules^{1,2} and pharmaceuticals.³ An efficient strategy to access a diverse array of amides is via the direct arylation of unfunctionalized amides.^{4,5} Although remarkable progress has been made in the palladium catalyzed α -arylation of ketones, esters,^{6,7,8} and oxindoles,⁹ limited examples of catalytic intermolecular α -arylation of amides have been reported.^{5a-c} This is most likely due to the high pK_a 's of amide α -C-H's¹⁰ and the potential formation of over-arylation byproducts.^{5a}

In pioneering investigations on the α -arylation of amides, Hartwig and co-workers demonstrated that aryl bromides reacted with *N,N*-dialkylacetamide derivatives in the presence of KN(SiMe₃)₂, catalytic Pd(dba)₂ and BINAP at 95–100 °C (Scheme 1, eq 1).^{5c} The α -arylation products were obtained in 48–72% yield. The moderate yields were partially due to formation of diarylated byproducts. In light of the challenging nature of this reaction, the scope of aryl bromides and acetamide derivatives reported was limited.

Fax: (+1)-215-573-6743; pwalsh@sas.upenn.edu.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/adsc.201300851>.

In 2006, Hartwig and co-workers introduced a two step approach to the palladium catalyzed arylation of zinc amide enolates,^{5b} which exhibited higher yields and broader substrate scope (Scheme 1, eq 2).^{5a} To circumvent the challenges of direct arylation, the zinc amide enolates¹¹ were generated by deprotonation of the amides with ^{sec}BuLi in the presence of ZnCl₂ at -78 °C.^{12,13,14} The resulting zinc enolates smoothly underwent palladium-catalyzed arylation at 25–70 °C. Despite these advances, more general, practical and atom-economical approaches for the α-arylation of amides remain desirable.

Following our interest in the catalytic functionalization of weakly acidic *sp*³-hybridized C–H bonds¹⁵ (*pK_a*'s 28–35 in DMSO), we developed approaches for deprotonative cross-coupling processes (DCCP), wherein *in situ* deprotonation of a substrate is performed in the presence of a palladium catalyst that promotes the arylation. Examples of substrates amenable to this approach include diarylmethanes,¹⁶ chromium-activated benzylic amines,¹⁵ sulfoxides¹⁷ and sulfones.^{18a} Based on our success with these substrates, we explored the palladium-catalyzed DCCP amides (*pK_a*>35) with aryl halides. Herein we report the selective mono- and bisarylation of *N,N*-dialkyl acetamide derivatives employing Kwong's indole-based palladium catalyst in the presence of alkoxide and amide bases (Scheme 1, eq 3). A portion of this work has been communicated.^{18b}

Results and Discussion

Given the high *pK_a*'s of amides and our successful direct arylation of sulfoxides¹⁷ (*pK_a* 32–35) and sulfones¹⁸ (*pK_a* 28–32) with palladium and Kwong's indole-based ligand **L** (Scheme 1, eq 3),¹⁹ we initiated our study with the same catalyst. The challenge was perceived to control the extent of arylation, because the monoarylation product is more acidic than the starting acetamide. Therefore, a second arylation could be problematic.²⁰

2.1. Optimization of Base and Solvent Combinations for the α-Arylation of Amides

Using 5 mol % Pd(OAc)₂ and 10 mol % Kwong's ligand **L**¹⁹ (Scheme 1, eq 3) at 110 °C in the presence of bromobenzene (**1a**, 2 equiv) and *N,N*-diethylacetamide (**2a**, 1 equiv) as coupling partners, we first set out to identify bases and solvents. The results of these experiments are summarized in Table 1. Six bases [LiO^tBu, NaO^tBu, KO^tBu, LiN(SiMe₃)₂, NaN(SiMe₃)₂, and KN(SiMe₃)₂] were examined in toluene and led to the mono-arylated product **3aa** in up to 60% yield. LiO^tBu was the most effective base under these conditions, affording **3aa** in 60% yield and the diarylated product **4aa** in 9% yield (entry 1). In contrast, NaO^tBu and KO^tBu led to mixtures of monoarylated **3aa** and diarylated **4aa** in approximately a 1:1 ratio (entries 2 and 3). Of the silylamide bases screened, NaN(SiMe₃)₂ generated the diarylation product **4aa** in quantitative assay yield (entry 5) and LiN(SiMe₃)₂ afforded diarylation product in 82% yield (entry 4). The stronger base KN(SiMe₃)₂ resulted in lower yields, most likely due to decomposition of starting materials (entry 6). It is interesting that the bases have such a strong impact on the ratios of the mono- and diarylated products, especially considering that the alkoxide bases are stronger than the silylamide bases in solvents like DMSO. With the optimal base in hand, three common solvents were next examined. Cyclopentyl methyl ether (CPME), dioxane and THF all afforded mixtures of mono- and bis-arylated products. With LiO^tBu as the base, less than 3:1 selectivity was

observed (entries 7–9). Lowering the temperature to 80 °C in toluene resulted in only trace formation of **3aa** (entry 10).

To improve the yield and selectivity for the mono-arylated product **3aa**, various Pd to phosphine ratios and Pd sources were investigated (Table 2). Interestingly, decreasing the catalyst loading from 5 mol % to 2.5 mol % resulted in an increase in the yield of **3aa** from 60% to 74% with only 8% of diarylated **4aa** (Table 2, entries 1–2).²¹ Further decreasing the catalyst loading to 2.0 or 1.25 mol % led to lower yields of monoarylated product (entries 2 vs 3–4). In addition, we found that Pd(dba)₂ generally gave lower yields than Pd(OAc)₂ (Table 2, entries 5 and 6 vs entries 1 and 2).

After Pd(OAc)₂ was identified as the palladium source with Kwong's ligand **L**, we examined the impact of the ratios of bromobenzene (**1a**) to amide **2a** (Table 3). In general, increasing the equivalence of amide **2a** resulted in higher yields of **3aa**. The best result was observed when the reaction was conducted with a 2:1 ratio of **2a**:**1a** (92% yield, Table 3, entry 1), where only trace amounts of **4aa** formed (~2%). When the equivalents of amide **2a** was lowered to 1.8, the yield decreased to 79% (entry 2). Use of 1.5 equiv **2a** provided the monoarylated product **3aa** in 82% yield while further decreasing **2a** to 1.2 equiv resulted in 85% yield of the monoarylation product and 6% bis-arylation (entries 3 and 4). Further experimentation indicated that moderate yields (60–71%) of **3aa** as well as 11–24% of bis-arylation byproduct **4aa** were obtained when 1.2–1.8 equiv of aryl bromide **1a** was employed (entries 5–7). Increasing or decreasing the reaction concentrations did not result in improved yields (entries 9 and 10). Thus, our best conditions for the synthesis of monoarylated amide **3aa** entailed 2 equiv of amide, 1 equiv of aryl bromide, and 3 equiv LiO^tBu in the presence of 2.5 mol % Pd(OAc)₂ and 5.0 mol % **L** in toluene at 110 °C for 12 h.

2.2. Scope of the Amide Arylation with Aryl Bromides

With optimized conditions in hand, the scope of aryl bromides was investigated with amide **2a** (Table 4). Aryl bromides with alkyl substituents (**1a–f**) were good substrates, providing the desired products in 88–94% yields. It is noteworthy that sterically demanding 2-bromotoluene (**1e**) and 1-bromonaphthalene (**1f**) generated the corresponding products in 93 and 88% yield, respectively. Aryl bromides with electron-donating groups, such as 4-methoxy (**1g**) and 4-*N,N*-dimethylamino (**1h**) underwent coupling reactions smoothly giving **3ag** and **3ah** in 95% and 89% yield, respectively. Aryl bromides with electron-withdrawing substituents, such as 4-bromofluorobenzene (**1i**), 4-bromochlorobenzene (**1j**) and 3-trifluoromethyl bromobenzene (**1k**), however, required slightly higher Pd(OAc)₂ (4 mol %) and ligand loadings (8 mol %) to achieve satisfactory yields (84–92%). Under the optimal conditions, the ratio of monoarylation to diarylation products in the crude reaction mixtures were greater than 15:1, as determined by ¹H NMR.

We next examined the reactivity of substrates with different substituents on acetamide nitrogen (Table 5).^{22,23} The arylation of pyrrolidine substituted amide (**2b**) proceeded in 85% yield at lower temperature (90 °C) with bromobenzene (**1a**). The piperidine (**2c**) and morpholine (**2d**) substituted amides coupled with bromobenzene to give the products **3ca**

and **3da** in 86 and 89% yield, respectively. In the case of the piperidine-substituted amide (**2c**), the loading of LiO^tBu was decreased to 2 equiv to avoid over-arylation. Both *N,N*-dimethyl- (**2e**) and *N,N*-diisopropylacetamides (**2f**) reacted with bromobenzene (**1a**) to form the mono-arylated products **3ea** and **3fa** in 88 and 91% yield, respectively. Extending the amide carbon chain to propionamide proved to be challenging, resulting in 46% yield of **3ga**, despite significant efforts to optimize this substrate. There are several factors that could account for the lower yield, including the higher p*K*_a of the α-C–H. A β-hydride elimination pathway is also possible, although no such products were isolated. Overall, the results in Tables 4 and 5 support the generality of the acetamide substrates.

2.3. Development of the Diarylation of Acetamides

To increase the diversity of products accessible by this method,²⁵ we developed a one-pot strategy to synthesize diarylated amides directly from acetamides. As described in Table 1 (entry 5), diarylated acetamide **4aa** was generated with good yield and excellent selectivity when NaN(SiMe₃)₂ was used as the base. A number of diarylated acetamides were readily prepared using a 2:1 ratio of aryl bromide to acetamide with 3 equiv NaN(SiMe₃)₂ (Table 6). Bromobenzene (**1a**), 4-*tert*-butyl bromobenzene (**1b**), 3-bromotoluene (**1d**) and 2-bromonaphthalene (**1l**) provided bis-arylation products in 92–95% yield. We also investigated the sterically hindered aryl bromides 2-bromotoluene (**1e**) and 1-bromonaphthalene (**1f**), providing the coupling products **4ee** and **4ff** in 86% and 87% yield, respectively. Electron-rich 4-bromoanisole (**1g**) also underwent coupling in good yield (88%). Use of electron-withdrawing 4-bromofluorobenzene (**1i**) proved to be more challenging, giving 81% yield of **4ii** at 10 mol % catalyst loading. To illustrate the potential of this protocol for preparative purposes, the reaction of amide **2c** with bromobenzene was carried out on a gram scale,²⁶ generating diarylated **4ca** in 92% yield (Scheme 2). Overall, the diarylation of amides outlined above provides easy access to diarylacetamides in high yield.

We were interested in extending the amide α-arylation to *N,N*-diethyl-2-phenylacetamide **3aa** with aryl bromides. Since the p*K*_a of **3aa**²⁷ is roughly 8 orders of magnitude lower than the corresponding acetamide **2a**,¹⁰ it is much easier to deprotonate the α-proton of **3aa** to generate the amide enolate. Unlike the arylation of acetamide derivatives, the use of LiO^tBu as the base was not optimal (32% yield, Table 7, entry 1). A short survey of bases revealed that NaO^tBu was the most suitable base under our conditions (Table 7, entry 2 vs 1, 3–6). The reaction furnished the product **4ab** in 95% yield when a 1.5:1 ratio of aryl bromide to amide was employed. However, when the ratio of aryl bromide to **3aa** was lowered to 1.2:1, the yield decreased to 81% (Table 7, entry 3). The yield also dropped to 75% using more reactive base KO^tBu (Table 7, entry 4). The data in Table 7 highlight the importance of the cation on this transformation.

The substrate scope of the monoarylation was investigated next. Various aryl bromides were screened under the optimized conditions using NaO^tBu as the base (Table 8). Similar yields for the synthesis of **4aa** and **4gg** were obtained from either monoarylated precursors **3aa** and **3ag** or acetamide derivative **2a** (Table 8 vs Table 6). We also treated **3aa** with various aryl bromides to generate diaryl acetamides with different aryl groups. Alkyl-substituted 4-*tert*-

butyl bromobenzene (**1b**) underwent coupling to give **4ab** in 91% yield. Sterically hindered 2-bromotoluene (**1e**) gave only 20% yield of desired product (**4ae**) under conditions using NaO^tBu. The yield was dramatically increased when NaN(SiMe₃)₂ was employed (91% yield). In all cases, the diarylacetamides were obtained in good to excellent yields using aryl bromides with either electron-donating substituents or electron-withdrawing substituents. The arylation of 4-bromoanisole (**1g**) afforded the products **4ag** in 90% yield. In contrast, aryl bromides with electron-withdrawing groups (**1i**, **1j**, **1k**) were found to be less reactive toward **3aa**. When the catalyst loading was increased to 5 mol %, the diarylated acetamides were isolated in 80–92% yield.

Amides derived from cyclic amines are important building blocks in the construction of biologically active compounds.^{28,29} Both pyrrolidine (**3ba**) and piperidine (**3ca**) acetamide derivatives were suitable substrates, coupling with 4-*tert*-butyl bromobenzene (**1a**) to provide the coupling products **4al** and **4am** in 92% and 94% yield respectively (Table 8).

Amides bearing other nitrogen substituents were also good substrates. Both *N,N*-dimethyl and *N*-methyl-*N*-phenyl precursors coupled with 4-*tert*-butyl bromobenzene to provide **4an** and **4ao** in 93 and 88% yield, respectively. Excellent yields were achieved for arylacetamide substrates bearing electron-donating 4-methoxy (**3ag**) or electron-withdrawing 4-chloro (**3aj**) on the arylacetamide precursors, with **4ap** furnished in 90% yield and **4aq** generated in 93% yield. Finally, we examined the reactivity of heterocyclic acetamide derivatives.³⁰ 3-Pyridyl and 3-thiophenyl *N,N*-diethylacetamides **3ar** and **3as** provided the corresponding products **4ar** and **4as** in 81 and 78% yields, respectively. Notably, no triarylated products were observed in any case, despite use of 1.5 equiv of aryl bromides.

We were interested in the application of our method to the synthesis of oxindoles (Scheme 3).⁹ Oxindoles are known to possess biological activities, and have been employed as substrates in racemic or enantioselective arylation reactions. Oxindoles are less challenging substrates for arylation than the amides outlined above, because of their increased acidity (*pK_a* 18.5 in DMSO).³¹ We were concerned that the oxindole product might undergo a second arylation under the reaction conditions. Upon subjecting the amide to our arylation conditions, however, the cyclized product **4da** was generated in 81% yield at 80 °C (Scheme 3). Thus, this catalytic system is effective for both inter- and intramolecular cross-coupling of amides with aryl bromides and arylation of the oxindole product is not a significant issue.

2.4. Optimization of the α -Arylation of Amides with Aryl Chlorides

Although α -arylation of amides with aryl bromides has been achieved, before our studies there were no examples of intermolecular arylation of amides with aryl chlorides.^{18b} In general, aryl chlorides are less reactive than aryl bromides in cross-coupling reactions.³² Nevertheless, aryl chlorides are less expensive and more abundant, so their use in the cross-coupling reactions is highly desirable. In the original report by the Hartwig group, BINAP was employed as ligand.^{5c} Same group later demonstrated that the mechanism of oxidative addition of aryl chlorides proceeds most readily through a palladium species bearing a single monodentate phosphine.³³ Palladium catalysts ligated with bidentate ligands activate C–Cl bond, but at temperatures around 100 °C.³⁴

Initial attempts to directly utilize chlorobenzene to replace bromobenzene with *N,N*-diethylacetamide **2a** under our standard conditions resulted in only 25% yield of **3aa**. Based on our previous experience with the arylation of sulfoxides with aryl chlorides,¹⁷ we hypothesized that catalyst activation might be problematic. We, therefore, employed the palladacyclic precursors (Figure 1), which have been demonstrated to readily form active catalysts.³⁵ As shown in Table 9, in order to identify the optimal reaction conditions, four common solvents [toluene, CPME, dioxane and dimethoxyethane (DME)] were screened using the μ -Cl Pd dimer³⁵ with Kwong's indole-based phosphine (**P1**, Figure 1). CPME was found to be the most suitable solvent under the conditions examined, affording a mixture of the mono- and bis-arylated products in a 5:1 ratio. From this mixture the monoarylated **3aa** was isolated in 63% yield (Table 9, entry 3). Other solvents were less effective which led to generation of **3aa** in lower yields (15–59%) and in lower ratios of mono- to bis-arylated products (Table 9, entry 3 vs 2, 4 and 5). Further survey of the six common bases [LiO^tBu, NaO^tBu, KO^tBu, LiN(SiMe₃)₂, NaN(SiMe₃)₂, and KN(SiMe₃)₂] showed that yields from 6–63% of mono-arylated **3aa** with mono-arylated **3aa** to bis-arylated **4aa** ratios of 2:1 to 5:1 (Table 9, entries 3 and 6–10). The yield and selectivity of **3aa** were not improved using μ -OMs Pd dimer³⁶ or the 3rd generation indole-based precatalyst³⁶ with chlorobenzene **5a** and *N,N*-diethylacetamide **2a** (Table 9, entries 11–12). Therefore, our best conditions for mono-arylation of acetamides with aryl chlorides were 2.5 mol % μ -Cl palladium dimer and 10 mol % **L** with 3 equiv LiO^tBu in CPME at 110 °C for 12 h.

2.5. Examination of the Scope of the Amide Arylation with Aryl Chlorides

Using the optimized reaction conditions, we investigated the substrate scope of aryl chlorides in the monoarylation with amide **2a** (Table 10). Chlorobenzene (**5a**) provided a 5:1 ratio of mono- : bis-arylated products from which the monoarylated product **3aa** was isolated in 63% yield. Similarly, alkyl substituted aryl chlorides such as 4-*tert*-butyl chlorobenzene (**5b**), 4-chlorotoluene (**5c**), 3-chlorotoluene (**5d**) and 3-chloro-*N,N*-dimethylaniline (**5l**) reacted with **2a** in moderate to good selectivities (5:1 – 10:1 mono- : bis-arylated product) and reasonable yields of the monoarylation products (63–72%). Sterically hindered aryl chlorides, such as 2-chlorotoluene and 1-chloronaphthalene, afforded <10% yield in this reaction, as did all other hindered aryl chlorides. This appears to be a limitation of the palladium catalyst with Kwong's indole-based phosphine. Electron-donating aryl chlorides, such as 4-chloroanisole (**5g**), gave the mono-coupled product in 70% yield and 10:1 selectivity. In contrast, lower selectivities (3:1 – 5:1) and reactivities were observed when electron-withdrawing aryl chlorides, such as 1-chloro-4-fluorobenzene (**5i**) and 1-chloro-3-(trifluoromethyl)benzene (**5k**), were employed. The increased acidity of the monoarylation products could result in the higher percentages of diarylated product. Nonetheless, the yields with these substrates (65–72%) were comparable to others in Table 10.

2.6. Development of the Diarylation of Acetamides with Aryl Chlorides

Our starting point for the bisarylation of acetamides with aryl chlorides was entry 6 of Table 9, where the bis-arylated **4aa** was formed in 20% yield in the presence of NaO^tBu and CPME. To increase the yield, palladacyclic precursors (Figure 1) were examined (Table 11).

We found that the 3rd generation indole phosphine-based precatalyst (**P3**, Figure 1) was the best Pd source in terms of yield (84%) when used with CPME solvent (Table 11, entry 1 vs entries 3 and 5). Two bases (NaO^tBu and KO^tBu) were also examined, as summarized in Table 11. Overall, NaO^tBu was more effective than KO^tBu with different Pd sources in the bisarylation of **2a** with aryl chlorides (Table 11, entries 1, 3, 5 vs entries 2, 4 and 6).

With the optimized conditions (entry 1 in Table 11) in hand, We next investigated the scope of the diarylation of *N,N*-diethylacetamide **2a** with a variety of aryl chlorides in the presence of 5 mol % 3rd generation indole-based precatalyst (**P3**). As shown in Table 12, 70–80% isolated yields were achieved for the diarylation. Chlorobenzene (**5a**), 4-*tert*-butyl chlorobenzene (**5b**), and 3-chlorotoluene (**5d**) afforded products **4aa**, **4bb** and **4dd** in 80, 76, and 70% yield, respectively. Electron-donating 4-chloroanisole (**5g**) gave the corresponding bis-coupling product **4gg** in 72%. Electron-withdrawing 1-chloro-4-fluorobenzene (**5i**) was also well tolerated in this reaction to provide **4ii** in 72% yield.

Having established a protocol for diarylation with aryl chlorides, we examined the arylation of arylacetamides to yield diarylated products **4** (Table 13). Since NaO^tBu was the best base for the diarylation of acetamides, it was used as the base for arylation of arylacetamides. In a short survey of palladacyclic precursors, the 3rd generation indole-based precatalyst (**P3**), provided the desired product **4aa** with 95% yield when 1.5 equiv chlorobenzene was employed (Table 13, entry 1). Moreover, we were delighted to find that even decreasing the loading of precatalyst from 5.0 mol % to 2.5 mol % still led to a satisfactory yield (91%, entry 2). Other Pd sources, such as μ -Cl Pd dimer (**P1**) and μ -OMs Pd dimer (**P2**), were also examined in arylation of **3aa** with chlorobenzene, but gave lower yields (Table 13, entries 3 and 4).

With our optimal conditions (NaO^tBu and 2.5 mol % of the indole-based precatalyst at 110 °C in CPME) we examined the substrate scope with different aryl chlorides (Table 14). The alkyl substituted 4-*tert*-butyl chlorobenzene (**5b**) and 3-chlorotoluene (**5d**) behaved well in the reactions with **3aa**, providing the desired diarylacetylides **4ab** and **4ad** in 95 and 93% yield, respectively. 3-Chloro-*N,N*-dimethylaniline (**5l**) generated the product **4at** in 90% yield. Electron-donating 4-chloroanisole (**5g**) and 4-pyrrolyl chlorobenzene (**5u**) were found to react with **3aa** to give **4ag** and **4au** in 88 and 91% yield, respectively. Similarly, electron-withdrawing 1-chloro-4-fluorobenzene (**5i**) reacted to provide **4ai** in 90% yield.

To further explore the substrate scope and limitations of this process, pyrrolidine (**3ba**) and piperidine (**3ca**) acetamide derivatives were found to be effective in providing arylation products **4al** and **4am** in 90 and 93% yield, respectively (Table 14). Substrates that bear heteroaryl groups on the acetamide, such as 3-pyridyl (**3ar**) and 3-thiophenyl (**3as**), underwent the α -arylation in 83 and 77% yield, respectively. It is noteworthy that changing the substituents on the amide nitrogen of the substrates had little impact on the arylation reactivity or yield.

Conclusions

The direct α -arylation of amides is challenging, because α -protons of amides have very high pK_a 's (up to 35 in DMSO⁹). Prior direct arylation of acetamides with aryl bromides introduced by Hartwig and co-workers resulted in formation of the arylation products in 48–72% yield. We introduced herein a more general and practical palladium-catalyzed direct α -arylation of acetamides with aryl halides. This chemistry relies on the indole-based phosphine introduced by Kwong and coworkers.¹⁹ A variety of mono- and bis-arylated acetamides were prepared in good to excellent yields. We also report that a palladacyclic precursor formed with the indole-based ligand effectively catalyzes the direct α -arylation of acetamides with aryl chlorides. It is noteworthy that the chemoselectivity between mono- and bis-arylated products was effectively controlled by choice of base, solvent, and stoichiometry. We demonstrated the catalyst exhibited excellent reactivity in intramolecular arylation to form oxindoles. The studies reported herein position us to examine the enantioselective arylation of aryl acetamides. Such studies are currently underway in our group.

Experimental Section

General Procedures

All reactions were conducted under an inert atmosphere of dry nitrogen. Anhydrous dioxane, CPME, and 2-MeTHF were purchased from Sigma-Aldrich and used without further purification. Dichloromethane and toluene were dried through activated alumina columns under nitrogen. Unless otherwise stated, reagents were commercially available and used as received without further purification. Chemicals were purchased from Sigma-Aldrich, Acros, or Matrix Scientific and solvents were obtained from Fisher Scientific. Flash chromatography was performed with Silica gel (230–400 mesh, Silicycle). NMR spectra were obtained using a Bruker 500 MHz Fourier-transform NMR spectrometer. The infrared spectra were obtained with KBr plates using a Perkin-Elmer Spectrum 1600 Series spectrometer. High resolution mass spectrometry (HRMS) data were obtained on a Waters LC-TOF mass spectrometer (model LCT-XE Premier) using chemical ionization (CI) or electrospray ionization (ESI) in positive or negative mode, depending on the analyte. Melting points were determined on a Unimelt Thomas-Hoover melting point apparatus and are uncorrected. *N,N*-diethylacetamide was purchased from Sigma-Aldrich and stored under nitrogen.

Procedures for the Pd-Catalyzed Arylation of Amides

General Procedure A—Monoarylation of Acetamide Derivatives with Aryl Bromides. An oven-dried microwave vial equipped with a stir bar was charged with Pd(OAc)₂ (1.1 mg, 0.0050 mmol) and ligand **L** (4.0 mg, 0.010 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry toluene via syringe. After the catalyst solution stirred for 90 min at 25 °C, LiO^tBu (48.3 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethylacetamide (46.0 mg, 0.40 mmol, 2.0 equiv) was added dropwise to this solution. The microwave vial was sealed and bromobenzene (21.2 μ L, 0.20 mmol, 1.0 equiv) was added by syringe under a nitrogen atmosphere. The reaction mixture was stirred at 110 °C for the

specified time then allowed to cool to room temperature. The reaction was quenched with H₂O (0.2 mL) and the resulting solution passed through a short pad of silica gel and eluted with ethyl acetate. The combined organics were dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the purified arylacetamide derivatives **3**. See the Supporting Information for full characterization all compounds.

General Procedure B—Diarylation of Acetamide Derivatives with Aryl Bromides. An oven-dried microwave vial equipped with a stir bar was charged with Pd(OAc)₂ (2.2 mg, 0.01 mmol) and ligand **L** (8.0 mg, 0.02 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry toluene via syringe. After the catalyst solution stirred for 90 min at 25 °C, NaN(SiMe₃)₂ (110.0 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethylacetamide (23.0 mg, 0.20 mmol, 1.0 equiv) was added dropwise to this solution. The microwave vial was sealed and bromobenzene (42.4 µL, 0.40 mmol, 2.0 equiv) was added by syringe under nitrogen atmosphere. The reaction mixture was stirred at 110 °C for the specified time then allowed to cool to room temperature. The reaction was quenched with H₂O (0.2 mL) and then was pass through a short pad of silica gel and eluted with ethyl acetate. The combined organics were dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the diarylacetamide derivatives **4**.

General Procedure C—Arylation of Arylacetamide Deravitives with Aryl Bromides. An oven-dried microwave vial equipped with a stir bar was charged with Pd(OAc)₂ (1.1 mg, 0.0050 mmol) and ligand **L** (4.0 mg, 0.010 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry toluene via syringe. After the catalyst solution stirred for 90 min at 25 °C, NaO^tBu (57.7 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethyl-2-phenylacetamide (38.2 mg, 0.20 mmol, 1.0 equiv) was added dropwise to this solution. The microwave vial was sealed and bromobenzene (31.8 µL, 0.30 mmol, 1.5 equiv) was added by syringe under a nitrogen atmosphere. The reaction mixture was stirred at 110 °C for the specified time then allowed to cool to room temperature. The reaction was quenched with H₂O (0.2 mL) and then was passed through a short pad of silica gel and eluted with ethyl acetate. The combined organics were dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the diarylated acetamide derivative **4**.

General Procedure D—Monoarylation of Acetamide Derivatives with Aryl Chlorides. An oven-dried microwave vial equipped with a stir bar was charged with µ-Cl Pd dimer (3.6 mg, 0.0050 mmol) and ligand **L** (8.1 mg, 0.020 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry CPME via syringe. After the catalyst solution stirred for 90 min at 25 °C, LiO^tBu (48.3 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethylacetamide (46.0 mg, 0.40 mmol, 2.0 equiv) was added dropwise. The microwave vial was sealed and chlorobenzene (20.3 µL, 0.20 mmol, 1.0 equiv) was added by syringe under a nitrogen atmosphere. The reaction was stirred at 110 °C for the specified time then allowed to cool to room temperature. The reaction mixture was quenched with H₂O (0.2 mL) and passed through a short pad of silica gel and eluted with ethyl acetate. The combined

organics dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield the monoarylated acetamide derivatives **3**.

General Procedure E—Diarylation of Acetamide Derivatives with Aryl Chlorides. An oven-dried microwave vial equipped with a stir bar was charged with 3rd generation precatalyst (7.7 mg, 0.010 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry CPME via syringe. After the catalyst solution stirred for 5 min at 25 °C, NaO^tBu (57.7 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethylacetamide (23.0 mg, 0.20 mmol, 1.0 equiv) was added dropwise to this solution. The microwave vial was sealed and chlorobenzene (40.6 µL, 0.40 mmol, 2.0 equiv) was added by syringe under a nitrogen atmosphere. The reaction was stirred at 110 °C for the specified time then allowed to cool to room temperature. The reaction mixture was quenched with H₂O (0.2 mL) and then passed through a short pad of silica gel and eluted with ethyl acetate. The combined organics were dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield diarylacacetamide derivatives **4**.

General Procedure F—Arylation of Arylacetamide Derivatives with Aryl Chlorides. An oven-dried microwave vial equipped with a stir bar was charged with the 3rd generation precatalyst (7.7 mg, 0.010 mmol) under a nitrogen atmosphere, followed by 1.0 mL dry CPME via syringe. After the catalyst solution stirred for 5 min at 25 °C, NaO^tBu (57.7 mg, 0.60 mmol, 3 equiv) was added to the reaction vial and *N,N*-diethyl-2-phenylacetamide (38.2 mg, 0.20 mmol, 1.0 equiv) was added dropwise to this solution. The microwave vial was sealed and chlorobenzene (30.4 µL, 0.30 mmol, 1.5 equiv) was added by syringe under a nitrogen atmosphere. The reaction was stirred at 110 °C for the specified time then allowed to cool to room temperature. The reaction mixture was quenched with H₂O (0.2 mL) and then was pass through a short pad of silica gel and eluted with ethyl acetate. The combined organics dried over Na₂SO₄ and concentrated in vacuo. The crude residue was purified by flash column chromatography to yield diarylated acetamide derivatives **4**.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Science Foundation [CHE-1152488] and National Institutes of Health (NIGMS 104349) for financial support. B.Z. thanks China Scholarship Council [2011635137] for financial support.

References

1. a) Haag BA, Zhang Z-G, Li J-S, Knochel P. *Angew. Chem. Int. Ed.* 2010; 49:9513–9516. b) Sheehan JC, Henery-Logan KR. *J. Am. Chem. Soc.* 1962; 84:2983–2990. c) Kaburagi Y, Tokuyama H, Fukuyama T. *J. Am. Chem. Soc.* 2004; 126:10246–10247. [PubMed: 15315428] d) Youshko MI, Svedas VK. *Adv. Synth. Catal.* 2002; 344:894–898.
2. a) Zou B, Long K, Ma D. *Org. Lett.* 2005; 7:4237–4240. [PubMed: 16146396] b) Maddess ML, Tackett MN, Watanabe H, Brennan PE, Spilling CD, Scott JS, Osborn DP, Ley SV. *Angew. Chem. Int. Ed.* 2007; 46:591–597. c) Liu X-Y, Fang Z-Z, Dong P-P, Shi X-H, Teng Y-J, Sun X-Y. *Pharmazie*. 2012; 67:804–808. [PubMed: 23016456] d) Tang H, Zhao H-T, Zhong S-M, Wang Z-Y, Chen Z-F, Liang H. *Bioorg. Med. Chem. Lett.* 2012; 22:2257–2261. [PubMed: 22341944]

3. a) Tanaka H, Kuroda A, Marusawa H, Hatanaka H, Kino T, Goto T, Hashimoto M, Taga T. *J. Am. Chem. Soc.* 1987; 109:5031–5033. b) Kantorova M, Kolinska R, Pazoutova S, Honzatko A, Havlicek V, Flieger M. *J. Nat. Prod.* 2002; 65:1039–1040. [PubMed: 12141870] c) Mu S-Z, Wang J-S, Yang X-S, He H-P, Li C-S, Di Y-T, Wang Y, Zhang Y, Fang X, Huang L-J, Hao X-J. *J. Nat. Prod.* 2008; 71:564–569. [PubMed: 18288811] d) Kuzma M, Sedmera P, Jegorov A, Havlicek V. *J. Nat. Prod.* 2009; 72:159–163. [PubMed: 19102681] e) Socha AM, LaPlante KL, Russell DJ, Rowley DC. *Bioorg. Med. Chem. Lett.* 2009; 19:1504–1507. [PubMed: 19185486]
4. a) Dugger RW, Ragan JA, Ripin DHB. *Org. Process Res. Dev.* 2005; 9:253–258. b) Busacca CA, Fandrick DR, Song JJ, Senanayake CH. *Adv. Synth. Catal.* 2011; 353:1825–1864. c) Magano J, Dunetz JR. *Chem. Rev.* 2011; 111:2177–2250. [PubMed: 21391570]
5. a) Hama T, Culkin DA, Hartwig JF. *J. Am. Chem. Soc.* 2006; 128:4976–4985. [PubMed: 16608331] b) Hama T, Liu X, Culkin DA, Hartwig JF. *J. Am. Chem. Soc.* 2003; 125:11176–11177. [PubMed: 16220921] c) Shaughnessy KH, Hamann BC, Hartwig JF. *J. Org. Chem.* 1998; 63:6546–6553. d) Kuendig EP, Seidel TM, Jia Y-X, Bernardinelli G. *Angew. Chem. Int. Ed.* 2007; 46:8484–8487. e) Luan X, Mariz R, Robert C, Gatti M, Blumentritt S, Linden A, Dorta R. *Org. Lett.* 2008; 10:5569–5572. [PubMed: 19053729] f) Luan X, Wu L, Drinkel E, Mariz R, Gatti M, Dorta R. *Org. Lett.* 2010; 12:1912–1915. [PubMed: 20349945] g) Liu L, Ishida N, Ashida S, Murakami M. *Org. Lett.* 2011; 13:1666–1669. [PubMed: 21384887] h) Tolstoy P, Lee SXY, Sparr C, Ley SV. *Org. Lett.* 2012; 14:4810–4813. [PubMed: 22946713] i) Wu L, Falivene L, Drinkel E, Grant S, Linden A, Cavallo L, Dorta R. *Angew. Chem., Int. Ed.* 2012; 51:2870–2873. j) Wasa M, Chan KSL, Zhang X-G, He J, Miura M, Yu J-Q. *J. Am. Chem. Soc.* 2012; 134:18570–18572. [PubMed: 23116159]
6. For reviews, see: Bellina F, Rossi R. *Chem. Rev.* 2010; 110:1082–1146. [PubMed: 19610600] Johansson CCC, Colacot TJ. *Angew. Chem. Int. Ed.* 2010; 49:676–707. Culkin DA, Hartwig JF. *Acc. Chem. Res.* 2003; 36:234–245. [PubMed: 12693921]
7. For recent reviews, see: Tobisu M, Chatani N. *Angew. Chem. Int. Ed.* 2006; 45:1683–1684. Jazzar R, Hitce J, Renaudat A, Sofack-Kreutzer J, Baudoin O. *Chem. - Eur. J.* 2010; 16:2654–2672. [PubMed: 20143359] Wasa M, Engle KM, Yu J-Q. *Isr. J. Chem.* 2010; 50:605–616. [PubMed: 21552359] Baudoin O. *Chem. Soc. Rev.* 2011; 40:4902–4911. [PubMed: 21505712] Bergman RG. *Nature.* 2007; 446:391–393. [PubMed: 17377575] Chen X, Engle KM, Wang D-H, Yu J-Q. *Angew. Chem. Int. Ed.* 2009; 48:5094–5115. Daugulis O, Do H-Q, Shabashov D. *Acc. Chem. Res.* 2009; 42:1074–1086. [PubMed: 19552413] Lyons TW, Sanford MS. *Chem. Rev.* 2010; 110:1147–1169. [PubMed: 20078038] Sun C-L, Li B-J, Shi Z-J. *Chem. Rev.* 2011; 111:1293–1314. [PubMed: 21049955] for recent reviews on general C–H arylation, see: Yu J-Q, Giri R, Chen X. *Org. Biomol. Chem.* 2006; 4:4041–4047. [PubMed: 17312954] Kakiuchi F, Kochi T. *Synthesis.* 2008:3013–3039. Ackermann L, Vicente R, Kapdi AR. *Angew. Chem. Int. Ed.* 2009; 48:9792–9826. McGracken GP, Bateman LM. *Chem. Soc. Rev.* 2009; 38:2447–2464. [PubMed: 19623360] Ackermann L. *Chem. Commun.* 2010; 46:4866–4877. Scheuermann CJ. *Chem. - Asian J.* 2010; 5:436–451. [PubMed: 20041458] Ackermann L. *Chem. Rev.* 2011; 111:1315–1345. [PubMed: 21391562] Wencel-Delord J, Droge T, Liu F, Glorius F. *Chem. Soc. Rev.* 2011; 40:4740–4761. [PubMed: 21666903] Yeung CS, Dong VM. *Chem. Rev.* 2011; 111:1215–1292. [PubMed: 21391561] Barluenga J, Valdes C. *Angew. Chem. Int. Ed.* 2011; 50:7486–7500. Novak P, Martin R. *Curr. Org. Chem.* 2011; 15:3233–3262. Johansson Seechurn CCC, Kitching MO, Colacot TJ, Snieckus V. *Angew. Chem. Int. Ed.* 2012; 51:5062–5085. Shao Z, Zhang H. *Chem. Soc. Rev.* 2012; 41:560–572. [PubMed: 21785803] Shen HC. *Appl. Transition Met. Catal. Drug Discovery Dev.* 2012:25–95.
8. a) Palucki M, Buchwald SL. *J. Am. Chem. Soc.* 1997; 119:11108–11109. b) Hamann BC, Hartwig JF. *J. Am. Chem. Soc.* 1997; 119:12382–12383. c) Satoh T, Kawamura Y, Miura M, Nomura M. *Angew. Chem. Int. Ed.* 1997; 36:1740–1742. d) Yeung PY, Chung KH, Kwong FY. *Org. Lett.* 2011; 13:2912–2915. [PubMed: 21545163]
9. a) Nicolaou KC, Hao J, Reddy MV, Rao PB, Rassias G, Snyder SA, Huang X, Chen DYK, Brenzovich WE, Giuseppone N, Giannakakou P, O'Brate A. *J. Am. Chem. Soc.* 2004; 126:12897–12906. [PubMed: 15469287] b) Marti C, Carreira EM. *Eur. J. Org. Chem.* 2003:2209–2219. c) Trost BM, Brennan MK. *Synthesis.* 2009:3003–3025. d) Reddy VJ, Douglas CJ. *Org. Lett.* 2010; 12:952–955. [PubMed: 20104898] e) Qian Z-Q, Zhou F, Du T-P, Wang B-L, Ding M, Zhao X-L, Zhou J. *Chem. Commun.* 2009:6753–6755. f) Beyer A, Buendia J, Bolm C. *Org. Lett.* 2012; 14:3948–3951. [PubMed: 22794114] g) Tomita D, Yamatsugu K, Kanai M, Shibasaki M. *J. Am. Chem. Soc.* 2009; 131:6946–6948. [PubMed: 19453193] h) Kato Y, Furutachi M, Chen Z, Mitsunuma H, Matsunaga

- S, Shibasaki M. J. Am. Chem. Soc. 2009; 131:9168–9169. [PubMed: 19522526] i) Cheng L, Liu L, Wang D, Chen Y-J. Org. Lett. 2009; 11:3874–3877. [PubMed: 19708700] j) Taylor AM, Altman RA, Buchwald SL. J. Am. Chem. Soc. 2009; 131:9900–9901. [PubMed: 19580273] k) Jiang K, Peng J, Cui H-L, Chen Y-C. Chem. Commun. 2009:3955–3957. l) He R, Ding C, Maruoka K. Angew. Chem. Int. Ed. 2009; 48:4559–4561. m) Bui T, Syed S, Barbas CF. J. Am. Chem. Soc. 2009; 131:8758–8759. [PubMed: 19499923] n) Linton EC, Kozlowski MC. J. Am. Chem. Soc. 2008; 130:16162–16163. [PubMed: 18998679] o) Yasui Y, Kamisaki H, Takemoto Y. Org. Lett. 2008; 10:3303–3306. [PubMed: 18582078] p) Zhou Y, Xi Y, Zhao J, Sheng X, Zhang S, Zhang H. Org. Lett. 2012; 14:3116–3119. [PubMed: 22667443] q) Altman RA, Hyde AM, Huang X, Buchwald SL. J. Am. Chem. Soc. 2008; 130:9613–9620. [PubMed: 18588302] r) Durbin MJ, Willis MC. Org. Lett. 2008; 10:1413–1415. [PubMed: 18321119]
10. The pK_a of *N,N*-dialkyl acetamides in DMSO are around 35.0, which are described in Bordwell Table. Bordwell FG. Acc. Chem. Res. 1988; 21:456–463.
11. For earlier examples of zinc enolate, see: Poller RC, Silver D. J. Organomet. Chem. 1978; 157:247–253. House HO, Crumrine DS, Teranishi AY, Olmstead HD. J. Am. Chem. Soc. 1973; 95:3310–3324. Bertrand J, Gorrichon L, Maroni P, Meyer R, Viteva L. Tetrahedron Lett. 1982; 23:1901–1904.
12. a) Cossy J, De Filippis A, Pardo DG. Org. Lett. 2003; 5:3037–3039. [PubMed: 12916975] b) Cossy J, de Filippis A, Pardo DG. Synlett. 2003:2171–2174. c) de Filippis A, Gomez Pardo D, Cossy J. Tetrahedron. 2004; 60:9757–9767.
13. de Filippis A, Pardo DG, Cossy J. Synthesis. 2004:2930–2933.
14. a) Hirano T, Li W, Abrams L, Krusic PJ, Ottaviani MF, Turro NJ. J. Org. Chem. 2000; 65:1319–1330. [PubMed: 10814091] b) Mladenova G, Chen L, Rodriguez CF, Siu KWM, Johnston LJ, Hopkinson AC, Lee-Ruff E. J. Org. Chem. 2001; 66:1109–1114. [PubMed: 11312936] c) Banerjee M, Emond SJ, Lindeman SV, Rathore R. J. Org. Chem. 2007; 72:8054–8061. [PubMed: 17880244] d) Wan S, Gunaydin H, Houk KN, Floreancig PE. J. Am. Chem. Soc. 2007; 129:7915–7923. [PubMed: 17547399] e) Tanaka Y, Kanai M, Shibasaki M. J. Am. Chem. Soc. 2010; 132:8862–8863. [PubMed: 20536134] f) Cacciuttolo B, Poulain-Martini S, Dunach E. Eur. J. Org. Chem. 2011; 2011:3710–3714. g) Clausen DJ, Wan S, Floreancig PE. Angew. Chem. Int. Ed. 2011; 50:5178–5181.
15. a) Zhang J, Stanciu C, Wang B, Hussain MM, Da C-S, Carroll PJ, Dreher SD, Walsh PJ. J. Am. Chem. Soc. 2011; 133:20552–20560. [PubMed: 22047504] b) McGrew GI, Stanciu C, Zhang J, Carroll PJ, Dreher SD, Walsh PJ. Angew. Chem. Int. Ed. 2012; 51:11510–11513. c) McGrew GI, Temaismithi J, Carroll PJ, Walsh PJ. Angew. Chem. Int. Ed. 2010; 49:5541–5544.
16. a) Zhang J, Bellomo A, Creamer AD, Dreher SD, Walsh PJ. J. Am. Chem. Soc. 2012; 134:13765–13772. [PubMed: 22816972] b) Bellomo A, Zhang J, Trongsiwat N, Walsh PJ. Chem. Sci. 2013; 4:849–857.
17. Jia T, Bellomo A, Baina KEL, Dreher SD, Walsh PJ. J. Am. Chem. Soc. 2013; 135:3740–3743. [PubMed: 23419158]
18. a) Zheng B, Jia T, Walsh PJ. Org. Lett. 2013; 15:1690–1693. [PubMed: 23517309] b) Zheng B, Jia T, Walsh PJ. Org. Lett. 2013; 15:4190–4193. [PubMed: 23909856]
19. a) So CM, Lau CP, Kwong FY. Org. Lett. 2007; 9:2795–2798. [PubMed: 17602563] b) Lee HW, Lam FL, So CM, Lau CP, Chan ASC, Kwong FY. Angew. Chem. Int. Ed. 2009; 48:7436–7439. c) So CM, Lau CP, Kwong FY. Chem. - Eur. J. 2011; 17:761–765. [PubMed: 21226087] d) Wong SM, So CM, Chung KH, Lau CP, Kwong FY. Eur. J. Org. Chem. 2012; 2012:4172–4177. e) You J, Verkade JG. Angew. Chem. Int. Ed. 2003; 42:5051–5053. f) Yeung PY, Tsang CP, Kwong FY. Tetrahedron Lett. 2011; 52:7038–7041.
20. a) Culkin DA, Hartwig JF. J. Am. Chem. Soc. 2002; 124:9330–9331. [PubMed: 12167001] b) Kawatsura M, Hartwig JF. J. Am. Chem. Soc. 1999; 121:1473–1478. c) Su W, Raders S, Verkade JG, Liao X, Hartwig JF. Angew. Chem. Int. Ed. 2006; 45:5852–5855. d) Wu L, Hartwig JF. J. Am. Chem. Soc. 2005; 127:15824–15832. [PubMed: 16277525] e) You J, Verkade JG. Angew. Chem. Int. Ed. 2003; 42:5051–5053. f) Fox JM, Huang X, Chieffi A, Buchwald SL. J. Am. Chem. Soc. 2000; 122:1360–1370.
21. Moradi WA, Buchwald SL. J. Am. Chem. Soc. 2001; 123:7996–8002. [PubMed: 11506555]
22. Szumna A. Chem. Soc. Rev. 2010; 39:4274–4285. [PubMed: 20882239]

23. Wasa M, Chan KSL, Zhang X-G, He J, Miura M, Yu J-Q. *J. Am. Chem. Soc.* 2012; 134:18570–18572. [PubMed: 23116159]
24. a) Nahm S, Weinreb SM. *Tetrahedron Lett.* 1981; 22:3815–3818. b) Sibi MP. *Org. Prep. Proced. Int.* 1993; 25:15–40. c) Kurosu M, Kishi Y. *Tetrahedron Lett.* 1998; 39:4793–4796. d) Badioli M, Ballini R, Bartolacci M, Bosica G, Torregiani E, Marcantoni E. *J. Org. Chem.* 2002; 67:8938–8942. [PubMed: 12467411] e) Kochi T, Ellman JA. *J. Am. Chem. Soc.* 2004; 126:15652–15653. [PubMed: 15571381]
25. a) Trost BM, Toste FD, Greenman K. *J. Am. Chem. Soc.* 2003; 125:4518–4526. [PubMed: 12683822] b) Trost BM, Frontier AJ. *J. Am. Chem. Soc.* 2000; 122:11727–11728. c) Trost BM, Xie J, Sieber JD. *J. Am. Chem. Soc.* 2011; 133:20611–20622. [PubMed: 22070545] d) Billingsley KL, Buchwald SL. *J. Org. Chem.* 2008; 73:5589–5591. [PubMed: 18576604]
26. Katritzky AR, He H-Y, Suzuki K. *J. Org. Chem.* 2000; 65:8210–8213. [PubMed: 11101375]
27. pK_a of *N,N*-diethyl-2-phenylacetamide C-H bond in DMSO: 26.6; Bordwell FG, Fried HE. *J. Org. Chem.* 1981; 46:4327–4331.
28. Humphrey JM, Chamberlin AR. *Chem. Rev.* 1997; 97:2243–2266. [PubMed: 11848900]
29. Carey JS, Laffan D, Thomson C, Williams MT. *Org. Biomol. Chem.* 2006; 4:2337–2347. [PubMed: 16763676]
30. a) Deng X, Roessler A, Brdar I, Faessler R, Wu J, Sales ZS, Mani NS. *J. Org. Chem.* 2011; 76:8262–8269. [PubMed: 21899258] b) Ramurthy S, Costales A, Jansen JM, Levine B, Renhowe PA, Shafer CM, Subramanian S. *Bioorg. Med. Chem. Lett.* 2012; 22:1678–1681. [PubMed: 22264479]
31. Bordwell FG, Fried HE. *J. Org. Chem.* 1991; 56:4218–4223.
32. a) Littke AF, Fu GC. *Angew. Chem. Int. Ed.* 2002; 41:4176–4211. b) Bedford RB, Cazin CSJ, Holder D. *Coord. Chem. Rev.* 2004; 248:2283–2321. c) Corbet J-P, Mignani G. *Chem. Rev.* 2006; 106:2651–2710. [PubMed: 16836296] d) Fu GC. *Acc. Chem. Res.* 2008; 41:1555–1564. [PubMed: 18947239] e) Lundgren RJ, Stradiotto M. *Chem. - Eur. J.* 2012; 18:9758–9769. [PubMed: 22786694] f) Rossi R, Bellina F, Lessi M. *Adv. Synth. Catal.* 2012; 354:1181–1255.
33. Lee S, Hartwig JF. *J. Org. Chem.* 2001; 66:3402–3415. [PubMed: 11348123]
34. a) Portnoy M, Milstein D. *Organometallics.* 1993; 12:1665–1673. b) Martinelli JR, Clark TP, Watson DA, Munday RH, Buchwald SL. *Angew. Chem. Int. Ed.* 2007; 46:8460–8463. c) Magerlein W, Indolese AF, Beller M. *Angew. Chem. Int. Ed.* 2001; 40:2856–2859.
35. a) Herrmann WA, Brossmer C, Ofele K, Reisinger C-P, Priermeier T, Beller M, Fischer H. *Angew. Chem. Int. Ed. Engl.* 1995; 34:1844–1848. b) Schnyder A, Indolese AF, Studer M, Blaser H-U. *Angew. Chem. Int. Ed.* 2002; 41:3668–3671. c) Kinzel T, Zhang Y, Buchwald SL. *J. Am. Chem. Soc.* 2010; 132:14073–14075. [PubMed: 20858009] d) Shu W, Buchwald SL. *Chem. Sci.* 2011; 2:2321–2325. e) Yang Y, Oldenhuis NJ, Buchwald SL. *Angew. Chem. Int. Ed.* 2013; 52:615–619. f) Biscoe MR, Fors BP, Buchwald SL. *J. Am. Chem. Soc.* 2008; 130:6686–6687. [PubMed: 18447360] g) Albert J, Granell J, Zafrilla J, Font-Bardia M, Solans X. *J. Organomet. Chem.* 2005; 690:422–429. h) Albert J, D'Andrea L, Granell J, Zafrilla J, Font-Bardia M, Solans X. *J. Organomet. Chem.* 2007; 692:4895–4902.
36. a) Bruno NC, Tudge MT, Buchwald SL. *Chem. Sci.* 2013; 4:916–920. [PubMed: 23667737] b) Bruno NC, Tudge MT, Buchwald SL. *Org. Lett.* 2013; 15:2876–2879. [PubMed: 23675976]

Figure 1.

μ -Cl and μ -OMs palladium dimers and the 3rd generation precatalyst bound to Kwong's indole-based phosphine (**L**).

Previous work **This work**

Scheme 1.
Intermolecular α -arylation of amides

Scheme 2. The α -arylation of amide (**2c**) with **1a** on gram scale.

Scheme 3.
Palladium-catalyzed intramolecular α -arylation.

Table 1

Optimization of the bases and solvents of α -arylation of *N,N*-diethylacetamide (**2a**) with bromobenzene (**1a**).^a

Entry	Bases	Solvent	Temp (°C)	3aa ^b (%)	4aa ^b (%)
1	LiO ^t Bu	Tol	110	60	9
2	NaO ^t Bu	Tol	110	36	38
3	KO ^t Bu	Tol	110	46	28
4	LiN(SiMe ₃) ₂	Tol	110	6	82
5	NaN(SiMe ₃) ₂	Tol	110	0	>95
6	KN(SiMe ₃) ₂	Tol	110	4	50
7	LiO ^t Bu	CPME	110	35	20
8	LiO ^t Bu	Dioxane	110	34	14
9	LiO ^t Bu	THF	80	15	6
10	LiO ^t Bu	Tol	80	trace	trace

^[a] Reactions performed using 2.0 equiv of **1a**, 1.0 equiv of **2a** and 3.0 equiv of base on a 0.2 mmol scale.

^[b] NMR yield.

Table 2

Optimization of the catalysts and Pd:L ratios in the α -arylation with bromobenzene (**1a**) and *N,N*-diethylacetamide (**2a**).^a

Entry	[Pd]/L /mol %	[Pd]	3aa ^b (%)	4aa ^b (%)
1	5/10	Pd(OAc) ₂	60	9
2	2.5/5	Pd(OAc) ₂	74	8
3	2/4	Pd(OAc) ₂	65	6
4	1.25/2.5	Pd(OAc) ₂	38	4
5	5/10	Pd(dba) ₂	65	12
6	2.5/5	Pd(dba) ₂	33	5

[^a] Reactions performed using 2.0 equiv of **1a**, 1.0 equiv of **2a** and 3.0 equiv of $LiOtBu$ on a 0.2 mmol scale.

[^b] NMR yield.

Table 3Optimization of the ratios of **1a**:**2a** in the α -arylation of amides.^a

Entry	2a:1a	3aa NMR yield (%)	4aa NMR yield (%)
1	2/1	92	2
2	1.8/1	79	4
3	1.5/1	82	10
4	1.2/1	85	6
5	1/1.2	62	13
6	1/1.5	71	11
7	1/1.8	60	24
8	1/2	74	8
9 ^b	2/1	79	1
10 ^c	2/1	83	2

^[a] Reactions performed using **1a**, **2a** and 3.0 equiv of LiO^tBu on a 0.2 mmol scale.^[b] Concentration was 0.1 mol/L.^[c] Concentration was 0.3 mol/L.

Table 4

Substrate scope of aryl bromides in the α -arylation with **2a**.^a ^[a] Reactions performed using 1.0 equiv of **1** and 2.0 equiv of **2a** on a 0.2 mmol scale.^[b] 4 mol % Pd(OAc)₂ and 8 mol % **L** used.

Table 5

Substrate scope of amides in the α -arylation with **1a**.^a ^[a] Reactions performed using 1.0 equiv of **1a**, 2.0 equiv of **2a** on a 0.2 mmol scale.^[b] 90 °C.^[c] 2.0 equiv LiOtBu employed.

Table 6

Substrate scope of aryl bromides in the diarylation with **2a**.^a ^[a]Reactions performed using 2.0 equiv of **1**, 1.0 equiv of **2a** on a 0.2 mmol scale.^[b]10 mol % Pd(OAc)₂ and 20 mol % **L** used.

Table 7Optimization of the monoarylation of **3aa** with **1b**.^a

Entry	Base	4ab NMR yield (%)
1	LiO ^t Bu	32
2	NaO ^t Bu	95 ^b
3	KO ^t Bu	75
4	LiN(SiMe ₃) ₂	63
5	NaN(SiMe ₃) ₂	55
6	KN(SiMe ₃) ₂	32
7	NaO ^t Bu	81 ^c

^[a] Reactions performed using 1.5 equiv of **1b**, 1.0 equiv of **3aa** and 3.0 equiv of base on a 0.2 mmol scale.^[b] 91% isolated yield.^[c] 1.2 equiv of **1b** employed.

Table 8

Substrates scope of aryl bromides and arylacetamides in the α -arylation.^a ^[a] Reactions performed using 1.5 equiv of **1**, 1.0 equiv of **3** on a 0.2 mmol scale.^[b] Using 2.0 equiv NaN(SiMe₃)₂.

$[c]$ 5 mol % Pd(OAc)₂ and 10 mol % **L** used.

Table 9Optimization of the α -arylation of *N,N*-diethylacetamide **2a** with chlorobenzene **5a**.^a

Entry	Base	Solvent	3aa ^b (%)	4aa ^b (%)
1 ^c	LiO ^t Bu	Toluene	25	trace
2	LiO ^t Bu	Toluene	59	14
3	LiO ^t Bu	CPME	63 ^d	12
4	LiO ^t Bu	Dioxane	34	14
5	LiO ^t Bu	DME	15	3
6	NaO ^t Bu	CPME	45	20
7	KO ^t Bu	CPME	50	14
8	LiN(SiMe ₃) ₂	CPME	12	trace
9	NaN(SiMe ₃) ₂	CPME	15	trace
10	KN(SiMe ₃) ₂	CPME	6	trace
11 ^e	LiO ^t Bu	CPME	36	14
12 ^f	LiO ^t Bu	CPME	29	15

^[a] Reactions performed using 1.5 equiv of **1a**, 1.0 equiv of **2a** on a 0.2 mmol scale.^[b] NMR yield.^[c] Using 2.0 equiv NaN(SiMe₃)₂.^[d] Isolated yield.^[e] 2.5 mol % **P2** and 10 mol % **L** used.^[f] 5.0 mol % **P3** used.

Table 10

Substrate scope of aryl chlorides in the monoarylation of **2a**.^a ^[a]Reactions performed using 1.0 equiv of **5**, 2.0 equiv of **2a** on 0.2 mmol scale.^[b]Ratio is mono- : bis-arylated product.

Table 11Optimization of the diarylation of *N,N*-diethylacetamide **2a** with **5a**.^a

Entry	[Pd]	Base	NMR yield (%)
1 ^b	P3	NaO ^t Bu	84
2 ^b	P3	KO ^t Bu	69
3	P2	NaO ^t Bu	69
4	P2	KO ^t Bu	50
5	P1	NaO ^t Bu	64
6	P1	KO ^t Bu	56

^[a] Reactions performed using 2.0 equiv of **1a**, 1.0 equiv of **2a** on a 0.2 mmol scale.^[b] 5 mol % **P3** used.

Table 12

Substrate scope of aryl chlorides in the diarylation of **2a**.^a ^[a] Reactions performed using 2.0 equiv of **5**, 1.0 equiv of **2a** on a 0.2 mmol scale.

Table 13Optimization of the conditions of the arylation of **3aa** with **5a**.^a

Entry	[Pd]	Catalyst /mol %	NMR yield (%)
1 ^b	P3	5	95
2 ^c	P3	2.5	91
3	P2	2.5	85
4	P1	2.5	76

^[a] Reactions performed using 1.5 equiv of **5a**, 1.0 equiv of **3aa** on a 0.2 mmol scale.^[b] 5 mol % **P3** used.^[c] 2.5 mol % **P3** used.

Table 14

Substrate scope of aryl chlorides in the α -arylation of arylacetamides.^a ^[a] Reactions performed using 1.5 equiv of **5**, 1.0 equiv of **3** on a 0.2 mmol scale.